Literature DB >> 27966241

Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients.

W Lin1, L Mou1, H Tu1, L Zhu2, J Wang1, J Chen1, Y Hu1.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Calcineurin inhibitor (CNI)-based immunosuppressive regimen is widely used for preventing rejection in solid organ transplantation. Hyperkalemic renal tubular acidosis (RTA) caused by CNI is uncommon and potentially underappreciated. We reported four such cases to increase awareness of this risk and to provide recommendations for its management based on our experience. CASE
SUMMARY: Four middle-aged males underwent solid organ transplant (two kidneys, one liver, one heart) and were treated with CNI-based immunosuppressive regimen (one cyclosporine A, three tacrolimus). On post-operative day 13-35, hyperkalemic hyperchloremic non-gap metabolic acidosis developed. All patients had relatively preserved renal function, normal urine output and plasma aldosterone level. Reduction in CNI dosage was partly effective; the patient on cyclosporine A was treated with fludrocortisone, and two others temporarily switched to sirolimus (SRL). WHAT IS NEW AND
CONCLUSION: We should alert for CNI-induced hyperkalemic RTA in transplant recipients. By CNI dosage reduction or adding low dose fludrocortisone, or temporarily switching to SRL, the prognosis of CNI-induced hyperkalemic RTA is favourable.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  calcineurin inhibitor; fludrocortisone; hyperkalemic renal tubular acidosis; sirolimus; solid organ; transplantation

Mesh:

Substances:

Year:  2016        PMID: 27966241     DOI: 10.1111/jcpt.12485

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  3 in total

Review 1.  The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?

Authors:  Samira S Farouk; Joshua L Rein
Journal:  Adv Chronic Kidney Dis       Date:  2020-01       Impact factor: 3.620

Review 2.  Renal Tubular Acidosis and Management Strategies: A Narrative Review.

Authors:  Biff F Palmer; Ellie Kelepouris; Deborah J Clegg
Journal:  Adv Ther       Date:  2020-12-26       Impact factor: 3.845

3.  Tacrolimus-Induced Type IV Renal Tubular Acidosis following Liver Transplantation.

Authors:  Christopher Schmoyer; Suraj Mishra; Frank Fulco
Journal:  Case Reports Hepatol       Date:  2017-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.